Prostate zonal impact of 5α‐reductase inhibitors on multiparametric <scp>MRI</scp> characteristics and detection of prostate cancer
Treatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.
Authors
- David F. Jarrard (ORCID: https://orcid.org/0000-0001-8444-7165)
- Giuseppe V. Toia (ORCID: https://orcid.org/0000-0001-5794-2822)
- Glenn O. Allen (ORCID: https://orcid.org/0000-0001-7720-9687)
- Christopher P. Filson (ORCID: https://orcid.org/0000-0002-8184-7275)
- Melina Pectasides
- Kayla Bahr
- Andrew M. Fang (ORCID: https://orcid.org/0000-0002-2390-7575)
- Arighno Das (ORCID: https://orcid.org/0000-0002-1736-5650)
- Soroush Rais‐Bahrami (ORCID: https://orcid.org/0000-0001-9466-9925)
- Emily E. Schmitt (ORCID: https://orcid.org/0000-0001-6965-9768)
- Hunter Boudreau (ORCID: https://orcid.org/0000-0002-5180-3140)
- Marcelo Bigarella (ORCID: https://orcid.org/0000-0002-7665-4794)
- Krista Brackman (ORCID: https://orcid.org/0000-0002-9978-3740)
Institutions
- Emory Healthcare (US)
- University of Wisconsin–Madison (US)
- Emory University (US)
- University of Alabama at Birmingham (US)
- University of Wisconsin Carbone Cancer Center (US)
- Wisconsin Division of Public Health (US)
- Atlanta VA Medical Center (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1111/bju.70067
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04